Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the ...

EVP Thompson explained the dose selection rationale and noted limited definitive evidence for GLP-1 efficacy in Prader-Willi. Analysts also raised concerns about DAYBUE's persistency metrics and ...

The Prader-Willi Syndrome Association USA estimates that PWS occurs in one in every 15,000 live births. The hallmark symptom of this disorder is hyperphagia, a chronic and life-threatening ...